Centre for Eye Research Australia(CERA)

What Centre for Eye Research Australia(CERA) does

Centre for Eye Research Australia (CERA) is an independent, not-for-profit medical research institute founded in 1996 in Melbourne by Laureate Professor Hugh Taylor, affiliated with the University of Melbourne and the Royal Victorian Eye and Ear Hospital. CERA conducts translational eye research spanning gene therapy, cell therapy, stem cell reprogramming, AI diagnostics, bionic eye implants, and advanced retinal imaging across major conditions including glaucoma, age-related macular degeneration (AMD), inherited retinal diseases, diabetic eye disease, and corneal conditions. The institute maintains a portfolio of proprietary IP assets in development — including OcuSwitch (topical anti-VEGF therapy), RNA base editing for Usher syndrome, Mirugen (retinal stem cell regeneration), Enlighten Imaging (hyperspectral retinal imaging), and multiple AI-powered screening tools — and operates the Lions Eye Donation Service, a joint venture eye bank that has facilitated over 7,000 corneal donations and 15,000+ transplants since 1991.

CERA generates revenue through a diversified non-profit model: government research grants (NHMRC, state-level investments including the AUD $10M Breakthrough Victoria grant), philanthropic donations from individuals, family foundations, corporate partners, and workplace giving, plus commercial income from Cerulea Clinical Trials — a fully owned subsidiary launched in 2024 that delivers Phase 1-4 ophthalmic clinical trials for pharmaceutical and medtech sponsors and reinvests revenue into research. The institute also operates Oculo, a cloud-based clinical communications network founded in 2015 and now used by 3,200 optometrists and 770 ophthalmologists across Australia and New Zealand. CERA ranks in the world's top 5 for ophthalmology research and serves as Australia's only WHO Collaborating Centre for the Prevention of Blindness.

Name

Centre for Eye Research Australia(CERA)

Legal name

Centre for Eye Research Australia

Website

https://cera.org.au

Company type

Private

Founded year

1996

Operating status

Operating

Headcount range

101–250 employees

Short description

CERA is an independent, not-for-profit medical research institute founded in 1996 in Melbourne, Australia, conducting translational eye research across gene therapy, stem cell, AI diagnostics, and clinical trials for glaucoma, AMD, and inherited retinal diseases.

Ownership category

akta.pro rank

Product category

Ophthalmic Medical Research

NAICS

Scientific Research and Development Services (5417), Other Scientific and Technical Consulting Services (54169), Other Scientific and Technical Consulting Services (541690)

SIC

Services-Medical Laboratories (8071), Services-Educational Services (8200)

akta.pro primary industry

Clinical Research Support (CRC/CTA) (EDAOAJAO)

akta.pro secondary industry

Clinical Research Ethics & Human Subjects Protection Authorities (IRB/REC Oversight) (HLAJACAG)

Keywords

• Ophthalmology research
• Clinical trial services
• Gene therapy development
• Eye disease diagnostics
• Corneal donation services

Headquarters

HQ city

Melbourne

HQ country

Australia

HQ region

Oceania

Offices3 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales

Revenue model

1. Clinical Trials Revenue: Cerulea Clinical Trials, a fully owned subsidiary of CERA, delivers commercial clinical trials sponsored by pharmaceutical and medtech companies. Income from these commercial trials is reinvested back into vision research, participant experience, and discovery research.
2. Philanthropy and Donations: Individual donors, family foundations, trusts and foundations, corporate partners, and workplace giving programs provide funding support. Major programs include monthly giving (CERA Luminaries), bequests and gifts in wills, event sponsorship, and in-kind support.
3. Government and Research Grants: Funding from government bodies including NHMRC grants, Centre for Clinical Research Excellence grants, and state government investments like the $10 million Breakthrough Victoria investment for Cerulea Clinical Trials.

Go-to-market motion1 record

Distribution channels5 records

Marketing channels9 records

Core offering

CERA is an independent not-for-profit medical research institute that conducts translational eye research across discovery science, clinical research, and technology development. Its commercial-grade clinical trial services are delivered through Cerulea Clinical Trials (a wholly-owned subsidiary operational from end-2024), and the organisation supplies donated corneal tissue through the Lions Eye Donation Service joint venture. CERA also operates the Consumer Program for patient engagement and maintains an IP pipeline of gene therapies, AI diagnostics, and regenerative medicine platforms available for partnership.

Product overview

The Centre for Eye Research Australia (CERA) is an independent Medical Research Institute affiliated with the University of Melbourne and the Royal Victorian Eye and Ear Hospital. The organization operates a portfolio of research programs and services focused on preventing vision loss and blindness. Core offerings include Cerulea Clinical Trials (a not-for-profit clinical trials centre delivering stage 1-4 ophthalmic trials), the Lions Eye Donation Service (an eye bank providing donated tissue for transplants and research), and the Consumer Program (integrating patient perspectives into research). The organization also maintains an IP Asset Pipeline of research projects and technologies available for partnership. Research spans 28 specialized areas including artificial intelligence, bionic eye, gene therapy, glaucoma, macular degeneration, and inherited retinal diseases. CERA ranks among the world's top 5 for ophthalmology research and serves as Australia's only WHO Collaborating Centre for the Prevention of Blindness.

Differentiator

Problem solved

Functional benefit

Brands

• Cerulea Clinical Trials: A state-of-the-art clinical trial centre delivering stage 1-1V ophthalmic clinical trials and the new home of clinical research at CERA. It is a fully owned subsidiary of CERA backed by a $10 million investment from Breakthrough Victoria.

Products and services

• Cerulea Clinical Trials A not-for-profit ophthalmic clinical trial centre based at the Royal Victorian Eye and Ear Hospital delivering Phase 1-4 trials for both investigator-initiated studies and commercial pharmaceutical and medtech sponsors. Income from commercial trials is reinvested into vision research.
• Lions Eye Donation Service Eye bank at the Royal Victorian Eye and Ear Hospital that coordinates consent, donation surgery, evaluation, and distribution of donated corneal tissue for transplant and medical research. Since 1991, has facilitated more than 7,000 corneal donations and provided tissue for over 15,000 transplants.
• CERA Clinical Trials Program CERA's portfolio of investigator-initiated clinical trials covering age-related macular degeneration, corneal conditions, diabetic retinopathy, glaucoma, and inherited retinal disease, delivered through CERA's research programs and Cerulea Clinical Trials.
• Consumer Program Program integrating insights and lived experience of people with eye diseases into research processes through a Consumer Advisory Group and partnerships with lived-experience collaborators who co-design research, review materials, and inform community engagement.
• IP Asset Pipeline and Partnership Portfolio Portfolio of research-stage technologies available for partnership and commercialisation, including OcuSwitch (anti-VEGF eye drop), RNA base editing for Usher syndrome, Mirugen (retinal stem cell regeneration), electrical stimulation AAV delivery, Enlighten Imaging hyperspectral imaging, OneRightEye 3D eye models, and AI diabetes complications screening.

Quantifiable outcome

• One in seven Australians over 50 has early AMD signs at risk of vision-threatening complications
• +5 more outcomes

Named customers4 records

Segments5 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability9 records

Feature10 records

Partnerships

Eight partnerships are on record, tiered core.

• University of MelbournecoreStrategic or Co-development PartnerCERA is proudly affiliated with the University of Melbourne, with teams based in discovery research labs including a state-of-the-art genetic engineering hub. Professor Hugh Taylor, who established CERA, is the Harold Mitchell Professor of Indigenous Eye Health at the university.
• Royal Victorian Eye and Ear HospitalcoreStrategic or Co-development PartnerCERA is affiliated with the Royal Victorian Eye and Ear Hospital. Cerulea Clinical Trials is based in the hospital, and the Lions Eye Donation Service operates as a joint venture between CERA and the hospital.
• World Health Organization (WHO)coreStrategic or Co-development PartnerCERA is Australia's only designated WHO Collaborating Centre for the Prevention of Blindness, working to reduce the global burden of vision impairment through international collaboration and knowledge sharing.
• Garvan Institute of Medical ResearchcoreStrategic or Co-development PartnerResearch collaboration on AMD study investigating the role of reticular pseudodrusen in severe macular degeneration, combining expertise in bioinformatics, AI, genetics, and clinical ophthalmology.
• Bionics InstitutecoreStrategic or Co-development PartnerCollaboration on development of the suprachoroidal retinal prosthesis (bionic eye) and neuroprotective devices aimed at slowing retinal disease progression.
• WEHI (Walter and Eliza Hall Institute)coreStrategic or Co-development PartnerPart of the Synergy High Risk AMD Project collaboration funded by NHMRC, working with CERA and University of Melbourne to understand progression of high-risk age-related macular degeneration.
• Consumer Advisory Group Members and Advocacy OrganisationscoreStrategic or Co-development PartnerConsumer Program partners people with lived experience of eye conditions with researchers through the Consumer Advisory Group, helping guide and inform research strategy and ensure real-world relevance.
• Diabetes AustraliacoreStrategic or Co-development PartnerCERA was a partner in advocacy for a national eye screening program for people with diabetes. In 2018, the Commonwealth Government announced KeepSight, a national diabetes eye screening program led by Diabetes Australia.

Scale indicators11 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• Moorfields Eye Hospital NHS Foundation Trust: UK-based eye hospital and research centre (with UCL Institute of Ophthalmology) conducting translational ophthalmology research and clinical trials across the same disease areas as CERA (glaucoma, AMD, inherited retinal disease). Most directly comparable peer globally in mission and structure.
• Singapore Eye Research Institute (SERI): Asia-Pacific eye research institute affiliated with Singapore National Eye Centre, conducting translational ophthalmology research, clinical trials, and population health studies. Highly comparable to CERA in scope, scale, and integration with a major eye hospital.
• Save Sight Institute: Australia-based ophthalmology research institute affiliated with the University of Sydney, focused on translational eye research and clinical trials. Direct domestic peer to CERA with overlapping disease focus and university-hospital integration model.
• Lions Eye Institute: Perth-based Australian ophthalmology research institute with clinical, research, and eye banking services. Direct domestic peer, including overlap with Lions-affiliated eye donation work and translational research programs.

Emerging players

• LV Prasad Eye Institute: Indian multi-centre eye care and research institute combining clinical service, research, and education across major ophthalmic diseases. Comparable in mission (translational eye research integrated with patient care) though operating at much larger clinical scale.
• Adverum Biotechnologies: Clinical-stage gene therapy company developing intravitreal therapies for AMD, diabetic retinopathy, and inherited retinal diseases. Overlaps directly with CERA's gene therapy pipeline (OcuSwitch, RNA editing, AAV delivery) as a commercial competitor and potential licensing partner.
• Eyenuk: AI-driven eye screening company with FDA-cleared autonomous diabetic retinopathy and AMD detection algorithms. Direct competitor to CERA's AI retinal screening pipeline and oculomics predictive analytics work.

Broad incumbents

• Bascom Palmer Eye Institute: University of Miami-based ophthalmology research and treatment centre, consistently ranked #1 in US ophthalmology. Comparable in research breadth and gene therapy/regenerative medicine programs, but operates within a much larger US academic medical centre.
• Wilmer Eye Institute, Johns Hopkins: Johns Hopkins-affiliated ophthalmology research and treatment centre with broad translational research, gene therapy, and clinical trial programs. Comparable in research scope but embedded in a major US university health system with significantly larger resources.
• Massachusetts Eye and Ear: Harvard Medical School-affiliated specialty hospital and research centre focused on ophthalmology and otolaryngology. Strong translational research portfolio including gene therapy programs comparable to CERA's inherited retinal disease work.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Facebookfacebook.com/CERA.eye
• LinkedInlinkedin.com/company/centre-for-eye-research-australia

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles7 records

Subsidiaries2 records

Funding overview

Funding rounds2 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Centre for Eye Research Australia(CERA)